



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : <b>A61K 31/4525, 31/445, A61P 1/00</b>		A1	(11) International Publication Number: <b>WO 00/30640</b> (43) International Publication Date: 2 June 2000 (02.06.00)
(21) International Application Number:	PCT/EP99/09048	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date:	16 November 1999 (16.11.99)	(30) Priority Data: 98203943.0 23 November 1998 (23.11.98) EP	
(71) Applicant ( <i>for all designated States except US</i> ): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Patent Department, Turnhoutseweg 30, B-2340 Beerse (BE).	(72) Inventor; and (75) Inventor/Applicant ( <i>for US only</i> ): SCHUURKES, Joannes, Adrianus, Jacobus [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).	(74) Agent: VERBERCKMOES, Filip; Janssen Pharmaceutica N.V., Patent Department – ext. 3355, Turnhoutseweg 30, B-2340 Beerse (BE).	Published <i>With international search report.</i>
<b>(54) Title:</b> USE OF PRUCALOPRIDE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DYSPEPSIA			
<b>(57) Abstract</b> The present invention is concerned with the use of prucalopride and pharmaceutically acceptable acid addition salts thereof for the manufacture of a medicament for the treatment of warm-blooded animals, including humans, suffering from dyspeptic symptoms.			

**FOR THE PURPOSES OF INFORMATION ONLY**


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## USE OF PRUCALOPRIDE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DYSPEPSIA

5 The present invention is concerned with the use of prucalopride and pharmaceutically acceptable acid addition salts thereof for the manufacture of a medicament for the treatment of warm-blooded animals, including humans, suffering from dyspeptic symptoms.

10 Prucalopride, which is the generic name for the (1:1) succinic acid addition salt of 4-amino-5-chloro-2,3-dihydro-N-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofuran-carboxamide, has enterokinetic properties, *i.e.* it has strong gastrointestinal prokinetic activities.



15 Prucalopride facilitates both cholinergic and non-cholinergic non-adrenergic (NANC) excitatory neurotransmission and stimulates colonic motility and defecation in animals. It has no affinity for 5-HT<sub>2A</sub> and 5-HT<sub>3A</sub> receptors but is a potent and selective agonist of 5-HT<sub>4</sub> receptors. Prucalopride induces giant contractions in the colon that are 20 propagated over the length of the colon as a peristaltic wave and therefore has significant motility enhancing effects on the large intestine.

Prucalopride is generically described in EP-0,445,862-A1, published on 11 September 1991, and is specifically disclosed in WO-96/16060, published on 30 May 1996.

25 The term prucalopride as used herein comprises the free base form and the pharmaceutically acceptable acid addition salts thereof. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for 30 example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids. The term addition salt as used hereinabove also comprises the solvates which prucalopride as well as the salts thereof, are able to form. Such solvates are for 35 example hydrates, alcoholates and the like.

Preferred pharmaceutically acceptable acid addition salts of 4-amino-5-chloro-2,3-dihydro-*N*-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofuran-carboxamide are the hydrochloric acid (1:1) addition salt and the succinic acid (1:1) addition salt.

5

In view of its enterokinetic properties, prucalopride is useful in the treatment of motility disorders of the intestinal system, such as, e.g. constipation, pseudo-obstruction, intestinal atony, post-operative intestinal atony, irritable bowel syndrome (IBS), and drug-induced delayed transit.

10

Unexpectedly, it was found that prucalopride is also useful to treat patients suffering from dyspeptic symptoms.

Dyspepsia, more commonly known as indigestion, is a very common disorder. In fact, 15 between 15 to 20 percent of the population suffers from it on a recurring basis.

Dyspepsia can originate from a number of causes. For instance dyspeptic symptoms can be caused by a disturbed accommodation of food, hypersensitivity either peripherally or centrally mediated, disturbed gastric emptying, disturbed electrical rhythm, disturbed antro-duodenal coordination, or an impaired response to the 20 intraluminal contents.

Recently it is also believed that in a number of patients suffering from dyspepsia, their dyspeptic symptoms may result from a decreased motility of the colon which keeps the colon in a more or less "filled" condition. It is believed that this feeling of a "full" colon 25 or the feeling of pressure exerted on the stomach due to a filled colon can cause an "upset" stomach resulting in a number of dyspeptic symptoms. Said "full" colon may also cause a reflexive inhibition of the stomach resulting in dyspeptic symptoms.

Dyspeptic symptoms are for example a lack of appetite, feeling of fullness, early satiety, 30 nausea, vomiting, bloating and gaseous eructation.

In view of the above described utility of prucalopride, it follows that the present invention also provides a method of treating warm-blooded animals, including humans, (generally called herein patients) suffering from dyspeptic symptoms such as, e.g. a lack 35 of appetite, feeling of fullness, early satiety, nausea, vomiting, bloating and gaseous eructation. Consequently a method of treatment is provided for relieving patients suffering from dyspeptic symptoms, in particular dyspeptic symptoms caused by a

decreased motility of the colon, by administering to said patients a therapeutically effective amount of prucalopride or a pharmaceutically acceptable acid addition salt thereof.

- 5 Hence, the present invention provides the use of prucalopride for the manufacture of a medicament for treating dyspeptic symptoms, in particular dyspeptic symptoms caused by a decreased motility of the colon. Both prophylactic and therapeutic treatment are envisaged.
- 10 To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection.
- 15 For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants,
- 20 binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid
- 25 solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
- 30 It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association
- 35 with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers,

-4-

injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

In general it is contemplated that a therapeutically effective amount would be from  
5 about 0.001 mg/kg to about 5 mg/kg body weight, preferably from about 0.01 mg/kg to  
about 0.5 mg/kg body weight. A method of treatment may also include administering  
the active ingredient on a regimen of between two or four intakes per day.

The amount of prucalopride, or a pharmaceutically acceptable acid addition salt thereof,  
10 required as daily dose in treatment will vary not only with the route of administration,  
the nature of the condition being treated and the age, weight and condition of the patient  
and will ultimately be at the discretion of the attendant physician. In general, however,  
a suitable daily dose will be in the range of from about 0.05 to about 200 mg per day, in  
particular from about 0.1 to 20 mg per day. more particular from about 0.5 to 10 mg per  
15 day. A suitable daily dose for use in prophylaxis will generally be in the same range. It  
may be appropriate to administer the required dose as two, three, four or more sub-  
doses at appropriate intervals throughout the day. Administration can be before or after  
the intake of food (*i.e.* preprandial or postprandial).

20 Experimental section.

The efficacy of prucalopride, or a pharmaceutically acceptable acid addition salt  
thereof, to treat subjects suffering from dyspeptic symptoms can be demonstrated by the  
following trial.

25 A group of healthy subjects is treated with an anti-diarrheal compound such as, e.g.  
loperamide, which causes a mild constipation in said subjects, *i.e.* the normal colon  
motility is reduced so that the subjects have a colon in a "filled" condition.

30 The group of subjects is split into a control group and a test group for treatment with  
prucalopride. The subjects in the test group are then treated with prucalopride.

Then, the subjects in both groups are served a standard breakfast consisting of four  
slices of bread, one slice of ham, one slice of cheese, butter, jelly and two cups of  
coffee or tea with, if desired, milk and/or sugar.

The number of subjects suffering from dyspeptic symptoms and the seriousness of the dyspeptic symptoms are recorded and compared between the test group and the control group.

5 The above described trial can be modified by treating the test group with prucalopride after the subjects have finished their meal. The trial can be done open, or blindfolded, using a randomized group of subjects.

Alternatively, out of a group of subjects suffering from dyspeptic symptoms, a  
10 sub-group of subjects can be selected also having reduced colon motility. Said  
sub-group can be given prucalopride, or a pharmaceutically acceptable acid addition  
salt thereof, either preprandial or postprandial and the reduction of the number or  
seriousness of the dyspeptic symptoms can be recorded.

15 Conversely, out of a group of subjects suffering from reduced colon motility, and  
therefore having a reduced stool frequency, a sub-group of subjects can be selected also  
having dyspeptic symptoms. Said sub-group can be given prucalopride, or a  
pharmaceutically acceptable acid addition salt thereof, either preprandial or  
postprandial and the reduction of the number or seriousness of the dyspeptic symptoms  
20 can be recorded.

Claims

1. Use of prucalopride or a pharmaceutically acceptable addition salt thereof for the manufacture of a medicament for the treatment of patients having dyspeptic symptoms.
- 5
2. Use according to claim 1 wherein the dyspeptic symptoms are caused by a decreased motility of the colon.
- 10
3. Use according to any of claims 1 to 2 wherein the pharmaceutically acceptable addition salt of prucalopride is the (1:1) succinic acid addition salt.
4. Use according to any of claims 1 to 3 wherein the dyspeptic symptoms comprise lack of appetite.
- 15
5. Use according to any of claims 1 to 3 wherein the dyspeptic symptoms comprise the feeling of fullness.
6. Use according to any of claims 1 to 3 wherein the dyspeptic symptoms comprise early satiety.
- 20
7. Use according to any of claims 1 to 3 wherein the dyspeptic symptoms comprise nausea and vomiting.
- 25
8. Use according to any of claims 1 to 3 wherein the dyspeptic symptoms comprise bloating or gaseous eructation.
9. Use according to any of claims 1 to 3 wherein the daily dose of prucalopride or a pharmaceutically acceptable addition salt thereof ranges from 0.05 mg to 200 mg per day.
- 30
10. Use according to claim 9 wherein the daily dose ranges from 0.1 mg to 20 mg per day.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 99/09048

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K31/4525 A61K31/445 A61P1/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 389 037 A (JANSSEN PHARMACEUTICA N.V.) 26 September 1990 (1990-09-26) abstract page 20, line 26 - line 33 ---	1-10
X	WO 96 16060 A (JANSSEN PHARMACEUTICA N.V.) 30 May 1996 (1996-05-30) cited in the application the whole document ---	1-10
X	EP 0 445 862 A (JANSEN PHARMACEUTICA N.V.) 11 September 1991 (1991-09-11) cited in the application page 21, line 36 - line 47 claims 1-3,7,9 -----	1-10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

11 January 2000

Date of mailing of the international search report

18/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl  
Fax: (+31-70) 340-3016

Authorized officer

Economou, D

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/09048

Patent document cited in search report		Publication date	Patent family member(s)	Publication date	
EP 0389037	A	26-09-1990	AT 128132 T AU 616838 B AU 5209190 A CA 2012432 A CN 1045781 A, B CY 1921 A DE 69022453 D DK 389037 T ES 2081340 T FI 101624 B FI 944076 A GR 3017992 T HK 131596 A HU 9500311 A IE 67184 B IL 93817 A IL 110397 A JP 2289566 A JP 2845341 B NO 176101 B NZ 232964 A PT 93531 A, B RU 2037492 C US 5552553 A US 5616738 A US 5521314 A US 5576448 A US 5554772 A US 5565582 A US 5616583 A US 5536733 A US 5602129 A US 5610157 A US 5739134 A US 5374637 A ZM 1290 A ZW 3390 A	15-10-1995 07-11-1991 27-09-1990 22-09-1990 03-10-1990 07-03-1997 26-10-1995 16-10-1995 01-03-1996 31-07-1998 05-09-1994 29-02-1996 26-07-1996 28-09-1995 06-03-1996 30-03-1995 26-05-1995 29-11-1990 13-01-1999 24-10-1994 26-07-1991 07-11-1990 19-06-1995 03-09-1996 01-04-1997 28-05-1996 19-11-1996 10-09-1996 15-10-1996 01-04-1997 16-07-1996 11-02-1997 11-03-1997 14-04-1998 20-12-1994 31-07-1992 23-10-1991	
WO 9616060	A	30-05-1996	AU 704043 B AU 4299296 A BG 101605 A BR 9509819 A CA 2205573 A CZ 9701555 A EP 0807110 A FI 972203 A HR 950571 A HU 77375 A IL 116101 A JP 9512832 T NO 972143 A NZ 297753 A PL 320297 A SK 65297 A TR 960495 A US 5948794 A US 5854260 A	15-04-1999 17-06-1996 27-02-1998 30-09-1997 30-05-1996 17-09-1997 19-11-1997 23-05-1997 31-08-1997 28-04-1998 17-08-1999 22-12-1997 09-05-1997 27-05-1998 15-09-1997 08-10-1997 21-07-1996 07-09-1999 29-12-1998	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte	Jinal Application No
PCT/EP 99/09048	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0445862	A 11-09-1991	AU 636012 B AU 7207991 A BG 60381 B CA 2037575 A CN 1054598 A,B CN 1054778 A CS 9100460 A FI 911096 A HR 930483 A HU 9500241 A IL 97018 A JP 2601566 B JP 4211685 A LT 846 A,B LV 10085 A,B NO 177424 B NZ 237189 A PL 168811 B PL 168384 B PL 168686 B PL 168693 B PL 168356 B PL 169238 B PT 96937 A,B SG 47482 A SI 9110396 A RU 2070884 C US 5185335 A US 5262418 A ZW 2391 A	08-04-1993 12-09-1991 31-01-1995 07-09-1991 18-09-1991 25-09-1991 15-10-1991 07-09-1991 31-12-1995 28-08-1995 27-11-1995 16-04-1997 03-08-1992 27-02-1995 10-05-1994 06-06-1995 25-11-1992 30-04-1996 29-02-1996 29-03-1996 29-03-1996 29-02-1996 28-06-1996 31-10-1991 17-04-1998 31-12-1997 27-12-1996 09-02-1993 16-11-1993 07-09-1992